These potential treatments are likely only relevant when cAMP signalling either drives the cancer or where it is linked to therapy resistance, as in melanomas [42], and where there is not overexpression of the GPCR of interest (which could indicate a different mechanism; e.g., DRD2 in gastric cancers [43]). Here, DRD2 is linked to gastric cancer.